Authors:

Quande Lin

The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou 450008, China

Abstract:

During the past few years, patients with relapsed or refractory multiple myeloma (RRMM) have been treated using bispecific antibodies (BsAbs) and dual-targeted chimeric antigen receptor T (CAR T) cells, as more and more patients were not adequately helped by at least three prior rounds of therapy. The most common combos are GPRC5D/CD3 and BCMA/CD3. According to clinical results, patients are more likely to experience stronger and longer-lasting responses. Here, we present the most recent information on BsAbs that target BCMA/CD3, GPRC5D/CD3, and BCMA/CD19 CAR T cells, as presented at the ASCO annual meeting in 2023.

Keywords:

Multiple myeloma, Bispecific antibody, CAR T, Clinical trial

Citation:

Quande Lin. Dual-targeting CAR-T cells and bispecific antibodies for multiple myeloma. World Journal of Medical Oncology 2023